Expanded immune cells and low-dose IL-2 for chronic GVHD
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests whether giving special immune cells (regulatory T cells) grown in a lab, along with a low dose of interleukin-2, can help people with chronic graft-versus-host disease (GVHD) that hasn't improved with steroids. GVHD is a complication after a stem cell transplant where donor cells attack the patient's body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a stem cell transplant from a donor who is a close match (7 or 8 out of 8 HLA markers), or a half-matched (haploidentical) donor.
- You are at least 2 years old.
- You have chronic GVHD that has not responded to at least 4 weeks of low-dose IL-2 injections under the skin.
- Your steroid dose has been stable for 2 weeks before joining, and no other immune-suppressing drugs have been added or stopped in the last 4 weeks.
- Your major organs and bone marrow are working well enough.
- Your donor is willing and able to provide cells to make the investigational treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether injecting special immune cells (Treg cells) from your transplant donor, along with a protein called IL-2, can help control chronic graft-versus-host disease (cGVHD) that hasn't responded well to steroids. It is for people who have had a stem cell transplant and still have moderate to severe cGVHD.
This trial tests a new treatment using special white blood cells (called Treg cells) to help control graft-versus-host disease (GVHD), a common complication after a stem cell transplant. The goal is to reduce GVHD symptoms without the serious side effects of high-dose steroids.
This study tests a new cell therapy (CK0802) for people with severe graft-versus-host disease (GVHD) that hasn't improved with standard steroid treatment. The treatment aims to control the immune response causing GVHD, potentially reducing symptoms and improving outcomes.
This Phase 1 study tests a new combination of medicines to prevent graft-versus-host disease (GVHD) after an allogeneic stem cell transplant. If it works well, it may lower the chance and severity of GVHD, which can affect skin, liver, and the gut.
This trial tests whether adding ruxolitinib to standard steroid treatment works better than steroids alone for people with moderate to severe chronic graft-versus-host disease (cGVHD). cGVHD is a condition where donor immune cells attack the body after a stem cell transplant.
This trial tests a two-step use of ATG (a drug that calms immune cells) to help prevent graft-versus-host disease (GVHD) in patients receiving a stem cell transplant from a donor. It may be an option for people with certain blood cancers or disorders who are getting a strong, marrow-clearing transplant.
Hear when a new Graft Versus Host Disease (cGvHD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.